Physician profile
Rami Abboud
NPI 1285900670
$5,310.39
in general payments reported to CMS, 2019-2025
26 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $143 · 2021: $202 · 2022: $117 · 2023: $1,164 · 2024: $1,870 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,472.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,572.29 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Janssen Biotech, INC. | $677.47 | 2023-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $628.54 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $459.75 | 2022-2025 | Xifaxan, Trulance |
| Covidien LP | $299.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.87 | 2023-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $227.63 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $210.10 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $199.39 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $139.51 | 2019-2025 | Ocaliva |
| Celgene Corporation | $118.10 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $93.67 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $72.19 | 2023-2024 | Linzess |
| Madrigal Pharmaceuticals | $63.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $51.73 | 2025 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $46.90 | 2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $46.66 | 2023 | |
| Sirtex Medical INC | $22.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.24 | 2020 | |
| Braintree Laboratories, INC. | $19.81 | 2024 | Sutab, Suflave |
| Boston Scientific Corporation | $18.14 | 2023 | Orcapod |
| Medtronic, INC. | $16.18 | 2021 | |
| Romark Laboratories, Lc | $15.47 | 2020 | |
| Merck Sharp & Dohme LLC | $14.17 | 2020 | |
| Medtronic Vascular, INC. | $14.12 | 2020 | |
| Daiichi Sankyo INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rami Abboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.